Literature DB >> 7471310

Mixed-function oxidase enzymes in adriamycin-sensitive and resistant sublines of P-388 leukemia.

A Mungikar, M Chitnis, B Gothoskar.   

Abstract

Levels of mixed-function oxidase (MFO) enzymes were measured in adriamycin(ADR)-sensitive murine leukemia P-388 and its ADR-resistant subline P-388/ADR. The subcellular fractions of the resistant cells showed decreased contents of MFO components, cytochrome P-450 and cytochrome b5, in comparison with the identically prepared fractions of the parental tumor. Similarly, the levels of 7-ethoxycoumarin O-deethylase and the rate of ascorbate induced lipid peroxidation in vitro showed lower values in resistant tumor cells than those of P-388 tumor cells. The observed differences in the two tumor cell types were found to be considerably enhanced if the tumor cells were exposed in vitro to ADR before fractionation. The magnitude of induction of the MFO enzymes was significantly greater in the ADR exposed P-388 cells. The corresponding inducibility was suppressed in the drug exposed resistant tumor cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7471310     DOI: 10.1016/0009-2797(81)90067-3

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  5 in total

Review 1.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Tumour cell resistance to anthracyclines--a review.

Authors:  S Kaye; S Merry
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. The Kyushu University Urological Oncology Group.

Authors:  S Naito; T Ueda; S Kotoh; A Iguchi; K Sagiyama; Y Hiratsuka; Y Osada; A Ariyoshi; T Omoto; J Kumazawa
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells.

Authors:  P R Twentyman; N E Fox; K A Wright; N M Bleehen
Journal:  Br J Cancer       Date:  1986-04       Impact factor: 7.640

Review 5.  Mechanisms of multidrug resistance and implications for therapy.

Authors:  T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1988-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.